The global molecular breast imaging market was valued at US$ 846.7 Million in 2022 and is expected to reach US$ 1.4 Billion by 2033. The screening application with around 56.7% value share, has topped the global market within the application category in 2022 and is expected to grow at a CAGR of close to 4.7% over the forecast period (2023-2033)
Market Outlook-
Key Market Attributes
| Market Size, 2022 | US$ 846.7 Million |
|---|---|
| Market Size, 2023 | US$ 883.4 Million |
| Market Size, 2033 | US$ 1.4 Billion |
| Value CAGR (2023 to 2033) | 4.8% |
Molecular breast imaging (MBI), also known as breasts specific gamma imaging (BSGI), is a diagnostic imaging modality using gamma cameras and radiopharmaceutical to identify breast cancer. Its uptake is influenced by factors like blood flow, mitochondrial activity, and physiologic factors.
Although not recommended for generalized screening, MBI is suitable for diagnostic evaluation, patients with contraindications to MRI, newly diagnosed breast cancer, and women with dense breast tissue.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for molecular breast imaging was around 18.6% of the overall US$ 4.55 Billion of the global breast imaging market in 2022.
Semi Annual Market Update
| Particular | Value CAGR |
|---|---|
| H1 | 4.27% (2022 to 2032) |
| H2 | 5.24% (2022 to 2032) |
| H1 | 3.85% (2023 to 2033) |
| H2 | 5.68% (2023 to 2033) |
MBI can reliably image subcentimeter cancers and produce projections similar to mammography, making it more integrated into clinical practice. There are various configurations of breast-specific gamma cameras, including single-headed and dual-headed models.
MBI involves injecting radiopharmaceutial technetium-99m sestimibi, Miraluma, into the venous system, and the patient is positioned while seated with the breast compressed between the detector and compression plate or two detectors in a dual-headed camera. The radiologist reviews initial images and can acquire additional images as needed.
Owed to the above factors, the global market is projected to grow at CAGR of 4.8% in forecasted period.
The molecular breast imaging (MBI) market is expected to grow due to the growing prevalence of dense breast tissue within the screening population, affecting large patient pool.
Traditional breast cancer detection methods, like mammography, are sensitivity-limited, causing false-negative results for individuals with dense breasts. MBI offers a promising solution for millions of individuals with dense breasts, offering high detection rates and negative predictive value as per Journal of Nuclear Medicine- Official Publication, Society of Nuclear Medicine 2022. It offers advantages over other supplemental screening methods like breast MRI, whole-breast ultrasound, and contrast-enhanced mammography.
With its safety, affordability, ease of access, quick imaging acquisition and interpretation times, and acceptable rates of false-positive findings, MBI is likely to witness increasing adoption in the market. Healthcare providers and patients alike are recognizing the benefits of this technology, leading to a higher demand for MBI systems and services.
The molecular breast imaging (MBI) market is poised for substantial growth due to its potential to significantly improve breast cancer detection rates while minimizing associated risks. Recent studies have demonstrated that the estimated benefit of MBI, in terms of deaths averted, far outweighs the estimated risk of lives lost, with the benefit-to-radiation risk ratio now approaching that of mammography. This critical finding instils confidence in the safety and efficacy of MBI as a powerful screening tool.
One of the key factors driving the market's expansion is the promising data from the prospective multicenter Density MATTERS trial (NCBI, 2022). This study compared MBI with tomosynthesis as a supplemental screening method for women with dense breasts. The results revealed an impressive incremental cancer detection rate of 9.3 per 1,000 screened. Such a high detection rate is a compelling indicator of MBI's superior capability to identify breast cancer, particularly in women with dense breast tissue, where traditional screening methods like mammography may have limitations.
Given these significant advancements and the robust evidence supporting MBI's benefits, the demand for molecular breast imaging technologies is expected to soar. Healthcare providers and patients alike are increasingly recognizing the value of MBI in improving early cancer detection, leading to better treatment outcomes and potentially saving lives.
As the awareness of MBI's advantages spreads, more medical facilities are likely to adopt this cutting-edge technology, fostering the growth of the MBI market and, more importantly, contributing to better breast cancer care worldwide.
Principal Consultant
MBI may require tiled image acquisitions if the breast size exceeds the field of view, making lesions near the chest wall and axillary lymph nodes difficult to visualize. MBI should not be scheduled within 4 half-lives of other 99mTc-based studies, positron emission tomography (PET) / computerized tomography (CT), or targeted radionuclide therapies due to photon energy window overlap.
However, it has limitations such as 28 to 40 minutes of an imaging examination, higher whole-body radiation exposure variable insurance coverage, the need for nuclear medicine licensing and coordination, and lack of widespread availability.
Further, The American College of Radiology does not currently recommend MBI for breast cancer imaging as an adjunctive breast cancer screening basis breast density.
These constraints underscore the difficulties that the molecular breast imaging market is facing.
| Country | Value CAGR |
|---|---|
| United States | 4.5% |
| Germany | 5.8% |
| United Kingdom | 5.1% |
| Japan | 5.0% |
| China | 5.1% |
| India | 4.9% |
The United States occupies 30.9% value share in 2022 globally.
The United States has large population suffering from breast cancer as well as those with dense breast tissue.
Growing efficiency of MBI backed by factors such as low false-positive rates, good recall rates, quick interpretation times, a low cost, minimal contraindications, and a strong negative predictive value has increased its demand for breast cancer screening in the United States. Thus making United States a prominent market for molecular breast imaging in North America region
Germany occupies 23.1% value share in 2022 with Europe. Expenditure on molecular breast imaging in 2022 was US$ 57.5 Million.
The current age-based mammographic breast cancer screening recommendation in Germany is for women aged 50-69, although new recommendations advise screening decisions should be based on individual risk.
Longer screening intervals may be suggested for low-risk women to minimize needless diagnostic procedures. Risk-adapted mammographic screening might help high-risk women while lowering expenses and stress on low-risk women. As a result, Germany tends to be a lucrative market for the molecular breast imaging industry.
In 2022, the China held a dominant stance in the East Asian market and contributed around US$ 54.9 Million.
Chinese patients have a younger median age of onset, resulting in longer follow-up and treatment periods. This increases the disease burden for individuals and society. Chinese women undergo breast cancer screening earlier to reduce disease burden and improve prognosis. China updates guidelines, conducts large-scale cohort studies, and standardized screenings. This will significantly increase survival and reduce mortality in the Chinese population. This makes China a large market for molecular breast imaging.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Market Growth Outlook by Key Modality
| Modality | Value CAGR |
|---|---|
| Single Head Gamma Camera | 5.1% |
| Dual Head Camera | 4.6% |
By modality, dual head camera covered 61.4% of global market share in 2022.
The dual-head system allows for simultaneous capture of breast images in the craniocaudal, medial, and lateral regions. The sensitivity of dual-head molecular breast imaging for tumors larger than 10 mm in diameter varies the most across blinded assessors. With the addition of the second detector head, the sensitivity for the tiniest breast cancers (diameters 5 mm) is improved. Thus, dual head camera are predicted to expand rapidly between 2023 and 2033.
Market Growth Outlook by Key Applications
| Application | Value CAGR |
|---|---|
| Screening | 4.7% |
| Diagnosis | 5.0% |
The market value of screening application in molecular breast imaging market is US$ 480.1 Million, representing for a sizable 56.7% market share in 2022.
MBI is a highly sensitive imaging technique that can detect breast cancer even in dense breast tissue. It has been shown to be more effective in detecting small tumours and lesions that may not be visible on mammogram. MBI has lower false-positive rate compared to other imaging modalities, such as MRI or ultrasound. This means that fewer women may be subjected to unnecessary follow-up tests or biopsies.
It offers a more comprehensive and accurate assessment of breast health, especially for women with dense breasts or other risk factors. It can be a valuable addition to the standard breast cancer screening protocols, improving early detection and potentially saving lives.
Market Growth Outlook by Key End Users
| End Users | Value CAGR |
|---|---|
| Hospital | 4.3% |
| Diagnostic Imaging Centers | 4.8% |
| Breast Cancer Care | 5.8% |
The hospitals have a considerable presence in the molecular breast imaging market, accounting for 41.4% of end users in 2022, and exhibiting a CAGR of 4.3% over the forecast period.
Hospitals have access to state-of-art imaging equipment, including specialized molecular breast imaging machines. This ensures that patients receive the most accurate and reliable imaging results for early detection and diagnosis of breast cancer. Hospitals often conduct clinical trials and research studies related to breast cancers and imaging technologies. It provides a holistic approach to breast cancer care, making it the preferred choice for end users in molecular breast imaging.
Innovations and acquisitions among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten molecular breast imaging. Collaboration in research, development, and commercialization leads to market expansion and the creation of new applications. Numerous large firms compete in the field of molecular breast imaging. Among the well-known players in this field are-
Similarly, recent developments related to the companies active within the molecular breast imaging market have been tracked by the team at Future Market Insights, which are available in the full report.
Related Market Growth Outlook Scenario
| Particulars | Value CAGR |
|---|---|
| Breast Cancer Drugs Market | 1.1% |
| Breast Biopsy Devices Market | 5.4% |
| Breast Lesion Localization Devices Market | 5.4% |
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Modality, Application, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The global market is worth US$ 846.7 Million in 2022.
The global market estimates for 2023 is around US$ 883.4 Million.
The global market is expected to reach US$ 1.4 Billion by the end of 2033, with a sales revenue expected to register 4.8% CAGR.
The global market grew at a CAGR of 3.9% between 2017 and 2022.
The United States dominated the global market contributing around US$ 262.0 Million in the year 2022.
Germany holds nearly 6.8% market share in the global market in 2022.
China accounted for a market value share of around 6.5% in 2022, in the global market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Modality Adoption/Usage Analysis 4.2. Products USP/ Features Analysis 4.3. Cancer Statistics, By Key Countries 4.4. Disease Epidemiology 4.5. Clinical Applications of Imaging Techniques in Diagnosis 4.6. Regulatory Landscape 4.6.1. Regulatory Frameworks in United States 4.6.2. Regulatory Frameworks in Europe 4.6.3. Regulatory Frameworks in India 4.6.4. Regulatory Frameworks in Australia 4.7. Porter’s Analysis 4.8. PESTLE Analysis 4.9. Value Chain Analysis 4.10. Unmet Needs 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure 5.1.2. Global Life Expectancy Market Outlook 5.1.3. Research and Development funding by Region 5.1.4. Global Breast Imaging Market Overview – Parent Market Analysis 5.2. Forecast Factors - Relevance and Impact 5.2.1. Top Companies Historical Growth 5.2.2. Increased Prevalence of Chronic Diseases 5.2.3. Technological Advancements in Molecular Diagnostics 5.2.4. New Product Launches 5.2.5. Increasing Focus on Cancer Diagnostics 5.2.6. Strategic Collaborations and Partnerships 5.2.7. Cost of Product 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Volume) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Volume (Units) Analysis, 2017 to 2022 6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market – Pricing Assessment 7.1. Regional Pricing Analysis 7.2. Pricing Break-up 7.3. Global Average Pricing Analysis Benchmark 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 8.2. Current and Future Market Size (US$ Million) Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 8.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Modality, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Modality, 2023 to 2033 9.3.1. Single Head Gamma Camera 9.3.2. Dual Head Camera 9.4. Market Attractiveness Analysis By Modality 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Application, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033 10.3.1. Screening 10.3.2. Diagnosis 10.4. Market Attractiveness Analysis By Application 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 11.3.1. Hospitals 11.3.2. Diagnostic Imaging Centers 11.3.3. Breast Cancer Care 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia 12.3.5. East Asia 12.3.6. Oceania 12.3.7. Middle East and Africa 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. United States 13.3.1.2. Canada 13.3.2. By Modality 13.3.3. By Application 13.3.4. By End User 13.4. Market Attractiveness Analysis By Region 13.4.1. By Country 13.4.2. By Modality 13.4.3. By Application 13.4.4. By End User 13.5. Market trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis and Forecast 13.8.1. United States Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Modality 13.8.1.2.2. By Application 13.8.1.2.3. By End User 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Modality 13.8.2.2.2. By Application 13.8.2.2.3. By End User 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Modality 14.3.3. By Application 14.3.4. By End User 14.4. Market Attractiveness Analysis By Region 14.4.1. By Country 14.4.2. By Modality 14.4.3. By Application 14.4.4. By End User 14.5. Market trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis and Forecast 14.8.1. Brazil Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Modality 14.8.1.2.2. By Application 14.8.1.2.3. By End User 14.8.2. Mexico Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Modality 14.8.2.2.2. By Application 14.8.2.2.3. By End User 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Modality 14.8.3.2.2. By Application 14.8.3.2.3. By End User 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. United Kingdom 15.3.1.2. Germany 15.3.1.3. Italy 15.3.1.4. France 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Nordic Countries 15.3.1.8. BENELUX 15.3.1.9. Rest of Europe 15.3.2. By Modality 15.3.3. By Application 15.3.4. By End User 15.4. Market Attractiveness Analysis By Region 15.4.1. By Country 15.4.2. By Modality 15.4.3. By Application 15.4.4. By End User 15.5. Market trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis and Forecast 15.8.1. United Kingdom Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Modality 15.8.1.2.2. By Application 15.8.1.2.3. By End User 15.8.2. Germany Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Modality 15.8.2.2.2. By Application 15.8.2.2.3. By End User 15.8.3. Italy Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Modality 15.8.3.2.2. By Application 15.8.3.2.3. By End User 15.8.4. France Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Modality 15.8.4.2.2. By Application 15.8.4.2.3. By End User 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Modality 15.8.5.2.2. By Application 15.8.5.2.3. By End User 15.8.6. Russia Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Modality 15.8.6.2.2. By Application 15.8.6.2.3. By End User 15.8.7. Nordic Countries Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Modality 15.8.7.2.2. By Application 15.8.7.2.3. By End User 15.8.8. BENELUX Market Analysis 15.8.8.1. Introduction 15.8.8.2. Market Analysis and Forecast by Market Taxonomy 15.8.8.2.1. By Modality 15.8.8.2.2. By Application 15.8.8.2.3. By End User 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction / Key Findings 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Thailand 16.3.1.4. Philippines 16.3.1.5. Malaysia 16.3.1.6. Vietnam 16.3.1.7. Rest of South Asia 16.3.2. By Modality 16.3.3. By Application 16.3.4. By End User 16.4. Market Attractiveness Analysis By Region 16.4.1. By Country 16.4.2. By Modality 16.4.3. By Application 16.4.4. By End User 16.5. Market trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis and Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Modality 16.8.1.2.2. By Application 16.8.1.2.3. By End User 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Modality 16.8.2.2.2. By Application 16.8.2.2.3. By End User 16.8.3. Thailand Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Modality 16.8.3.2.2. By Application 16.8.3.2.3. By End User 16.8.4. Philippines Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Modality 16.8.4.2.2. By Application 16.8.4.2.3. By End User 16.8.5. Malaysia Market Analysis 16.8.5.1. Introduction 16.8.5.2. Market Analysis and Forecast by Market Taxonomy 16.8.5.2.1. By Modality 16.8.5.2.2. By Application 16.8.5.2.3. By End User 16.8.6. Vietnam Market Analysis 16.8.6.1. Introduction 16.8.6.2. Market Analysis and Forecast by Market Taxonomy 16.8.6.2.1. By Modality 16.8.6.2.2. By Application 16.8.6.2.3. By End User 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction / Key Findings 17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Modality 17.3.3. By Application 17.3.4. By End User 17.4. Market Attractiveness Analysis By Region 17.4.1. By Country 17.4.2. By Modality 17.4.3. By Application 17.4.4. By End User 17.5. Market trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis and Forecast 17.8.1. China Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Modality 17.8.1.2.2. By Application 17.8.1.2.3. By End User 17.8.2. Japan Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Modality 17.8.2.2.2. By Application 17.8.2.2.3. By End User 17.8.3. South Korea Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Modality 17.8.3.2.2. By Application 17.8.3.2.3. By End User 18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction / Key Findings 18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Modality 18.3.3. By Application 18.3.4. By End User 18.4. Market Attractiveness Analysis By Region 18.4.1. By Country 18.4.2. By Modality 18.4.3. By Application 18.4.4. By End User 18.5. Market trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis and Forecast 18.8.1. Australia Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Modality 18.8.1.2.2. By Application 18.8.1.2.3. By End User 18.8.2. New Zealand Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Modality 18.8.2.2.2. By Application 18.8.2.2.3. By End User 19. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction / Key Findings 19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. Northern Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Modality 19.3.3. By Application 19.3.4. By End User 19.4. Market Attractiveness Analysis By Region 19.4.1. By Country 19.4.2. By Modality 19.4.3. By Application 19.4.4. By End User 19.5. Market trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis and Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Modality 19.8.1.2.2. By Application 19.8.1.2.3. By End User 19.8.2. Türkiye Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Modality 19.8.2.2.2. By Application 19.8.2.2.3. By End User 19.8.3. South Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Modality 19.8.3.2.2. By Application 19.8.3.2.3. By End User 19.8.4. Northern Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Modality 19.8.4.2.2. By Application 19.8.4.2.3. By End User 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players (%) 20.3. Market Concentration 21. Competition Analysis 21.1. Competition Dashboard 21.2. Branding and Promotional Strategies, By Key Players 21.3. Key Development Analysis 21.4. Competition Deep Dive 21.4.1. Koninklijke Philips N.V. (Netherlands) 21.4.1.1. Overview 21.4.1.2. Product Portfolio 21.4.1.3. Key Financials 21.4.1.4. Sales Footprint 21.4.1.5. SWOT Analysis 21.4.1.6. Strategy Overview 21.4.1.6.1. Marketing Strategies 21.4.1.6.2. Product Strategies 21.4.1.6.3. Channel Strategies 21.4.2. Hitachi Ltd. (Japan) 21.4.2.1. Overview 21.4.2.2. Product Portfolio 21.4.2.3. Key Financials 21.4.2.4. Sales Footprint 21.4.2.5. SWOT Analysis 21.4.2.6. Strategy Overview 21.4.2.6.1. Marketing Strategies 21.4.2.6.2. Product Strategies 21.4.2.6.3. Channel Strategies 21.4.3. Siemens Healthcare GmbH (Germany) 21.4.3.1. Overview 21.4.3.2. Product Portfolio 21.4.3.3. Key Financials 21.4.3.4. Sales Footprint 21.4.3.5. SWOT Analysis 21.4.3.6. Strategy Overview 21.4.3.6.1. Marketing Strategies 21.4.3.6.2. Product Strategies 21.4.3.6.3. Channel Strategies 21.4.4. CANON MEDICAL SYSTEMS CORPORATION (Japan) 21.4.4.1. Overview 21.4.4.2. Product Portfolio 21.4.4.3. Key Financials 21.4.4.4. Sales Footprint 21.4.4.5. SWOT Analysis 21.4.4.6. Strategy Overview 21.4.4.6.1. Marketing Strategies 21.4.4.6.2. Product Strategies 21.4.4.6.3. Channel Strategies 21.4.5. General Electric (US) 21.4.5.1. Overview 21.4.5.2. Product Portfolio 21.4.5.3. Key Financials 21.4.5.4. Sales Footprint 21.4.5.5. SWOT Analysis 21.4.5.6. Strategy Overview 21.4.5.6.1. Marketing Strategies 21.4.5.6.2. Product Strategies 21.4.5.6.3. Channel Strategies 21.4.6. Aspect Imaging Ltd (Israel) 21.4.6.1. Overview 21.4.6.2. Product Portfolio 21.4.6.3. Key Financials 21.4.6.4. Sales Footprint 21.4.6.5. SWOT Analysis 21.4.6.6. Strategy Overview 21.4.6.6.1. Marketing Strategies 21.4.6.6.2. Product Strategies 21.4.6.6.3. Channel Strategies 21.4.7. Bruker (US) 21.4.7.1. Overview 21.4.7.2. Product Portfolio 21.4.7.3. Key Financials 21.4.7.4. Sales Footprint 21.4.7.5. SWOT Analysis 21.4.7.6. Strategy Overview 21.4.7.6.1. Marketing Strategies 21.4.7.6.2. Product Strategies 21.4.7.6.3. Channel Strategies 21.4.8. Aurora Health Care (US) 21.4.8.1. Overview 21.4.8.2. Product Portfolio 21.4.8.3. Key Financials 21.4.8.4. Sales Footprint 21.4.8.5. SWOT Analysis 21.4.8.6. Strategy Overview 21.4.8.6.1. Marketing Strategies 21.4.8.6.2. Product Strategies 21.4.8.6.3. Channel Strategies 21.4.9. FONAR Corp. (US) 21.4.9.1. Overview 21.4.9.2. Product Portfolio 21.4.9.3. Key Financials 21.4.9.4. Sales Footprint 21.4.9.5. SWOT Analysis 21.4.9.6. Strategy Overview 21.4.9.6.1. Marketing Strategies 21.4.9.6.2. Product Strategies 21.4.9.6.3. Channel Strategies 21.4.10. ESAOTE SPA (Italy) 21.4.10.1. Overview 21.4.10.2. Product Portfolio 21.4.10.3. Key Financials 21.4.10.4. Sales Footprint 21.4.10.5. SWOT Analysis 21.4.10.6. Strategy Overview 21.4.10.6.1. Marketing Strategies 21.4.10.6.2. Product Strategies 21.4.10.6.3. Channel Strategies 21.4.11. Neusoft Corporation (China) 21.4.11.1. Overview 21.4.11.2. Product Portfolio 21.4.11.3. Key Financials 21.4.11.4. Sales Footprint 21.4.11.5. SWOT Analysis 21.4.11.6. Strategy Overview 21.4.11.6.1. Marketing Strategies 21.4.11.6.2. Product Strategies 21.4.11.6.3. Channel Strategies 21.4.12. TOSHIBA CORPORATION (Japan) 21.4.12.1. Overview 21.4.12.2. Product Portfolio 21.4.12.3. Key Financials 21.4.12.4. Sales Footprint 21.4.12.5. SWOT Analysis 21.4.12.6. Strategy Overview 21.4.12.6.1. Marketing Strategies 21.4.12.6.2. Product Strategies 21.4.12.6.3. Channel Strategies 21.4.13. Sanrad Medical Systems Private Limited (India) 21.4.13.1. Overview 21.4.13.2. Product Portfolio 21.4.13.3. Key Financials 21.4.13.4. Sales Footprint 21.4.13.5. SWOT Analysis 21.4.13.6. Strategy Overview 21.4.13.6.1. Marketing Strategies 21.4.13.6.2. Product Strategies 21.4.13.6.3. Channel Strategies 21.4.14. FUJIFILM Holdings Corporation (Japan) 21.4.14.1. Overview 21.4.14.2. Product Portfolio 21.4.14.3. Key Financials 21.4.14.4. Sales Footprint 21.4.14.5. SWOT Analysis 21.4.14.6. Strategy Overview 21.4.14.6.1. Marketing Strategies 21.4.14.6.2. Product Strategies 21.4.14.6.3. Channel Strategies 21.4.15. ONEX Corporation (Canada) 21.4.15.1. Overview 21.4.15.2. Product Portfolio 21.4.15.3. Key Financials 21.4.15.4. Sales Footprint 21.4.15.5. SWOT Analysis 21.4.15.6. Strategy Overview 21.4.15.6.1. Marketing Strategies 21.4.15.6.2. Product Strategies 21.4.15.6.3. Channel Strategies 21.4.16. Hologic, Inc. (US) 21.4.16.1. Overview 21.4.16.2. Product Portfolio 21.4.16.3. Key Financials 21.4.16.4. Sales Footprint 21.4.16.5. SWOT Analysis 21.4.16.6. Strategy Overview 21.4.16.6.1. Marketing Strategies 21.4.16.6.2. Product Strategies 21.4.16.6.3. Channel Strategies 21.4.17. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China) 21.4.17.1. Overview 21.4.17.2. Product Portfolio 21.4.17.3. Key Financials 21.4.17.4. Sales Footprint 21.4.17.5. SWOT Analysis 21.4.17.6. Strategy Overview 21.4.17.6.1. Marketing Strategies 21.4.17.6.2. Product Strategies 21.4.17.6.3. Channel Strategies 21.4.18. Imaging Diagnostic Systems, Inc. (US) 21.4.18.1. Overview 21.4.18.2. Product Portfolio 21.4.18.3. Key Financials 21.4.18.4. Sales Footprint 21.4.18.5. SWOT Analysis 21.4.18.6. Strategy Overview 21.4.18.6.1. Marketing Strategies 21.4.18.6.2. Product Strategies 21.4.18.6.3. Channel Strategies 21.4.19. Agfa-Gevaert Group (Belgium) 21.4.19.1. Overview 21.4.19.2. Product Portfolio 21.4.19.3. Key Financials 21.4.19.4. Sales Footprint 21.4.19.5. SWOT Analysis 21.4.19.6. Strategy Overview 21.4.19.6.1. Marketing Strategies 21.4.19.6.2. Product Strategies 21.4.19.6.3. Channel Strategies 21.4.20. Koning Health (China) 21.4.20.1. Overview 21.4.20.2. Product Portfolio 21.4.20.3. Key Financials 21.4.20.4. Sales Footprint 21.4.20.5. SWOT Analysis 21.4.20.6. Strategy Overview 21.4.20.6.1. Marketing Strategies 21.4.20.6.2. Product Strategies 21.4.20.6.3. Channel Strategies 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Molecular Breast Imaging Market
